BioCentury
ARTICLE | Company News

Cytogen, Cellcor deal

September 25, 1995 7:00 AM UTC

The companies' stockholders will meet on Oct. 16 to address the proposed merger of CLTX into CYTO. CYTO shareholders will be asked to approved the issuance of up to 12 million shares of CYTO common for use in the acquisition of the 5.9 million shares outstanding of CLTX (see BioCentury June 19). CLTX's shareholders will be asked to approve the merger, under which they will receive 0.6 shares of CYTO common for each CLTX share, and 218.94 CYTO shares for each of the 5,250 shares of CLTX preferred shares outstanding. ...